ASLAN Firms Up IPO Plans As Lead Asset Progresses

Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.

Cancer cell

More from Immuno-oncology

More from Anticancer